A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 months. Amyloid PET scans will be conducted at screening, 9, and 18 months in Part 1. Participants who are at or below 11 CL at screening or reach complete amyloid plaque clearance as measured by florbetapir F18 PET (defined as ≤11 CL) at 9 months will initiate Part 2. Participants who are ≤11 CL at screening may delay their entry into Part 2 for up to 6 months at the discretion of the Investigator. All remaining participants will start Part 2 after completing 18 months (76 weeks) in Part 1 independent of amyloid results. Non-carriers will receive placebo in both Parts 1 and 2.
In Part 2, study participants who are mutation carriers will be randomized 1:1:1:1 in a full factorial design to receive either RG6289 + placebo-donanemab (RG6289 alone group), donanemab + placebo-RG6289 (donanemab alone group), the combination of RG6289 and donanemab (combination group), or placebo-RG6289 and placebo-donanemab (placebo group). All non-carriers will be assigned to the placebo group. CDR-GS at the end of Part 1 and the amyloid level using the last completed amyloid PET scan in Part 1 will be used for stratification. All study participants will participate in a double-dummy design for the duration of Part 2 receiving both an intravenous (IV) infusion at the required interval for the donanemab or matching placebo as well as a daily oral treatment of RG6289 or matching placebo.
An exploratory outcome of Part 1 is a comparison of the amyloid clearance between this ADAD cohort and historical controls using propensity score matching. The primary outcome in Part 2 is change from the start of Part 2 through the end of Part 2 in brain amyloid load in PSEN1 E280A mutation carriers as measured by amyloid PET imaging. Other endpoints will include fluid and imaging biomarkers and measures of cognition and functioning. The maximum study duration for any individual participant will be 3 years, not including the screening or follow-up periods

Start Date15 Jan 2026

Sponsor / Collaborator

Banner Health

[+2]

NCT06911944

/ Not yet recruitingPhase 4IIT

A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome

The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 years old and will be in the study for 12 months. Participants will then stay in the study for an additional 12 months in an long-term extension where all participants will receive donanemab. Participants who had a reduction in amyloid (measured by amyloid brain scan) by the end of the first 12 months will receive placebo for the long-term extension, while participants who did not have an amyloid reduction will receive study donanemab for the long-term extension. Everyone (participants and study staff) will remain blinded to treatment for the duration of the study.
Participants will:
* Have intravenous (IV) infusions of donanemab (or placebo) every 4 weeks
* Visit the clinic once every other month for checkups and tests. These tests will include brain scans (magnetic resonance imaging [MRI] and positron emission tomography [PET] ), blood draws and memory tests.
* Have a study partner who who can provide information about the participant and can join participant for some of the study visits.

Start Date01 Dec 2025

Sponsor / Collaborator

University of Southern California

[+3]

NCT06566170

/ RecruitingNot Applicable

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

Start Date07 Oct 2024

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Donanemab-AZBT

100 Translational Medicine associated with Donanemab-AZBT

100 Patents (Medical) associated with Donanemab-AZBT

246

Literatures (Medical) associated with Donanemab-AZBT

01 Feb 2026·Neural Regeneration Research

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Article

Author: Guo, Wanshu ; Sha, Sha ; Ren, Lina ; Qu, Le ; Li, Ying ; Cao, Yunpeng ; Xing, Xiaona ; Wang, Yan

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.

01 Nov 2025·JPAD-Journal of Prevention of Alzheimers Disease

Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries

Review

Author: Shea, Yat Fung ; Tan, Lolita Stephanie ; Park, Kee Hyung ; Prusty, Vinay ; Hsu, Jung-Lung ; Panegyres, Peter K ; Eom, Young In ; Huang, Yao Hsien

Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. Reviews of AD prevalence and diagnostic and treatment patterns typically focus on global or western populations, but the situation in Asia, Australasia, and Pacific Nations (AAPN) countries is less clear. We performed a narrative review of literature for AD in several AAPN countries, focusing on patients with MCI or mild dementia who may benefit from early treatment. Published information regarding AD incidence and prevalence and current practice in AAPN countries is limited and the nature of available information differs between countries. However, AAPN countries include some of the most rapidly aging populations and show the associated increasing trend of all-cause dementia prevalence observed globally. Although lecanemab and donanemab are now approved for AD with MCI and mild dementia in several AAPN countries, the most appropriate diagnostic pathway for patients with MCI and early AD is not established. Even though the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment. Guidelines and national policies also need updating to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD.

01 Nov 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Mapping the evolving landscape of lecanemab research in Alzheimer's Disease: A bibliometric analysis

Article

Author: Xu, Dingwen ; Shen, Jiaxing ; Ma, Ruijia ; Yang, Zhe ; Zhao, Xu

BACKGROUND:

Lecanemab, a monoclonal antibody that targets amyloid-beta aggregates, has emerged as a promising therapeutic for Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by cognitive decline and amyloid pathology. Research on the use of lecanemab in treating AD has increased; however, no relevant bibliometric analyses have been conducted. To address this gap, this study employed bibliometric methods to search for the relevant literature and analyze research trends investigating AD and lecanemab.

METHODS:

We performed a literature search of the Web of Science core database for studies investigating AD and lecanemab, published from database inception up to April 3rd, 2025. After rigorous screening, Excel, VOSviewer, and CiteSpace were used to perform a bibliometric analysis of publications, citations, and collaboration networks among countries, institutions, and authors, along with cluster and burst analyses of keywords. Coremine was used for text mining entries significantly related to AD and lecanemab.

RESULTS:

The number of studies published on AD and lecanemab has increased annually. The countries with the highest publication output were the United States, the United Kingdom, and China. The leading institutions that produced the most articles were Eisai Inc. (Bunkyo City, Tokyo, Japan), Uppsala University (Uppsala, Sweden), and Harvard Medical School (Boston, MA, USA). The top three authors were Lars Lannfelt, Shobha Dhadda, and Michio Kanekiyo. The most prolific journals included The Journal of Alzheimer's Disease, Alzheimer's and Dementia, and Ageing Research Reviews. The most cited article was "Lecanemab in Early Alzheimer's Disease," by Van Dyck et al., published in The New England Journal of Medicine in 2023, which has accrued 172 citations. The 10 most frequently occurring keywords were Alzheimer's disease, lecanemab, dementia, aducanumab, amyloid-beta, immunotherapy, tau, a-beta, mouse model, and donanemab. Text mining revealed that drugs, anatomical structures, chemical molecules, genes, diseases, and procedures were significantly associated with both AD and lecanemab.

CONCLUSION:

The bibliometric and text mining analysis revealed trends in research investigating the correlation between lecanemab and AD. It analyzed the cooperation among countries, regions, and authors, highlighting recent research hotspots. These data offer objective insights for scientific research and clinical practice on lecanemab and AD. These findings provide a roadmap for prioritizing clinical trials, optimizing drug development strategies, and addressing knowledge gaps in amyloid-targeted therapies.

570

News (Medical) associated with Donanemab-AZBT

15 Oct 2025

·www.pharmaceutical-technology.com

Healthcare burden of neurological conditions “growing”, WHO warns

While neurological disorders represent a significant burden on patient and healthcare systems alike, there are some promising developments in Alzheimer’s drug development. Image source: haydenbird, Royalty Free via Getty Images. A new report from the World Health Organization (WHO) has highlighted the global healthcare burden of neurological disorders. In the latest ‘Global status report on neurology’, the government organisation estimated that more than 40% of the global population is impacted by at least one neurological disorder, making the category the most common cause of ill health or disability worldwide. According to the WHO, conditions under the neurology umbrella account for 11 million deaths each year. This is despite the preventable nature of many of the diseases in this category. Alzheimer’s disease – one of the top 10 neurological conditions linked to death and disability – is still a huge burden on patients and healthcare systems alike, with the WHO report revealing that it received the most amount of research funding of all the neurological disorders in 2023. This has led to the development of effective treatments, though Dr Jeremy Farrar, WHO assistant director-general for health promotion, disease prevention and control, noted that “services remain out of reach for most”. Farar stated that this was especially true in low-income countries, which experience significant healthcare disparities due to a lack of access to specialists, low government budget allocations and a scarcity of national plans centred around treating these conditions. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Despite this, there have been some strong developments in the neurology field as of late – particularly in Alzheimer’s disease. Progress in Alzheimer’s disease treatment Although there is still no cure for Alzheimer’s disease, there have been some notable advancements in the indication, with two disease-modifying therapies (DMTs) getting the US Food and Drug Administration (FDA) green light in the last two years. The approved DMTs are Biogen and Eisai’s Leqembi (lecanemab) , and Eli Lilly’s Kisunla (donanemab) , which both work by clearing amyloid plaques from the brain. Leqembi and Kisunla both got the FDA go-ahead after they were shown to slow Alzheimer’s progression in patients with early-stage disease . Moving forward, the drugs will go head-to-head for market share, with GlobalData forecasting that Kisunla will make $2.4bn for Eli Lilly at its peak in 2031. However, analysts foresee that Leqembi will outperform Kisunla on the market, making $2.7bn in 2031, while going on to increase profits until 2033, as per a GlobalData report . GlobalData is the parent company of Clinical Trials Arena . This is all in the context of the Alzheimer’s disease market’s strong growth, which is projected to be worth $19.3bn across the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) by 2033 due to the continued market entry of DMTs. Despite their projected global success, both Biogen-Eisai and Eli Lilly’s drugs were denied for use in the UK’s National Health Service (NHS) after the National Institute for Health and Care Excellence (NICE) deemed them too expensive, despite their capacity to slow disease progression . Meanwhile, on the research front, there are a range of Phase III trials to watch in Alzheimer’s disease that could hold similar potential to Kisunla and Leqembi. These include Eli Lilly’s other Alzheimer’s amyloid plaque-clearing med, remternetug, Annovis Bio’s buntanetap tartrate, which inhibits amyloid-beta, tau and amyloid synuclein and AriBio’s phosphodiesterase 5 (PDE5) inhibitor, AR-1001. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Drug ApprovalPhase 3

14 Oct 2025

·www.fiercebiotech.com

Roche nabs FDA clearance for Alzheimer\'s biomarker blood test

Roche said it currently has more than 4,500 instruments in U.S. clinical labs that can handle the new blood test, giving primary care clinicians a jump on early diagnoses that could lead to improved treatments.\n Roche, which currently has investigational Alzheimer’s disease drug trontinemab in phase 3 trials, has secured FDA clearance of its blood-based biomarker test for the condition.The minimally invasive Elecsys pTau181 test was developed in collaboration with Eli Lilly. It’s designed to help assess early signs of Alzheimer’s and other causes of cognitive decline in primary care settings for patients 55 years and older, by ruling out Alzheimer’s-related amyloid pathology, according to an Oct. 13 release.Roche said it currently has more than 4,500 instruments in U.S. clinical labs that can handle the new blood test, giving primary care clinicians a jump on early diagnoses that could lead to improved treatments.Alzheimer’s impacts more than 7 million Americans and has multiple pathologies, contributing to the estimated 92% of patients with mild cognitive impairment who go undiagnosed, per Roche.“By bringing Alzheimer\'s blood-based biomarker testing into primary care, we can help patients and their clinicians get answers sooner to support them earlier in their journeys,” Brad Moore, Roche’s president and CEO of North American diagnostics, said in the release. The test—touted by the company as the first of its kind—measures phosphorylated Tau (pTau) 181 protein in human plasma, which is a key biomarker for Alzheimer\'s pathology, including amyloid plaque and tau aggregate pathology.The FDA clearance comes in the wake of the test garnering CE mark certification in Europe in July.Earlier this month, Lilly called for European countries to make urgent improvements to their Alzheimer’s disease diagnostic testing practices. That callout came after the company received new approval on the continent for its Alzheimer\'s therapy Kisunla, which was approved stateside last year.

$Roche nabs FDA clearance for Alzheimer\'s biomarker blood test$

Phase 3Drug Approval

14 Oct 2025

·www.biospace.com

Roche, Lilly Win First FDA Nod for Alzheimer’s Blood Test for Primary Care Use

iStock/ wildpixel Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s Eisai-partnered Leqembi, with CEO Chris Viehbacher recently noting that such biomarker-based tests could “remove some of the bottlenecks” in uptake. The FDA has given the go-ahead to Roche and Eli Lilly’s blood-based test to aid the initial assessment of cognitive decline in Alzheimer’s disease. The Elecsys pTau181 test is the only one of its kind approved for use in the primary care setting. Elecsys is now indicated for patients 55 years and older who show signs or complain of cognitive decline, according to Roche’s Sunday press release. The test, which measures blood levels of the phosphorylated Tau (pTau) 181 protein, can help primary care providers rule out Alzheimer’s disease-related pathology in patients with cognitive decline, though its results “should be interpreted in conjunction with other clinical information,” the companies said. Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, which have largely struggled to gain a footing in the market. During its second quarter 2025 report, Biogen CEO Chris Viehbacher specifically pointed to these biomarker tests as a potential catalyst to improve Leqembi’s market position. Such tests, he told investors, could “remove some of the bottlenecks in the system.” Data from more than 300 patients supported Sunday’s approval, demonstrating that Elecsys had a 97.9% negative predictive value at ruling out Alzheimer’s pathology. Roche and Lilly collaborated on Elecsys under a March 2023 partnership aimed at the earlier detection of Alzheimer’s disease. Elecsys is not the first blood test for Alzheimer’s disease. That came in May this year when the FDA approved Fujirebio Diagnostics’ Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, also indicated for use in patients 55 years and older. As in the case of Roche’s test, Lumipulse must also be used alongside other clinical assessments, the regulator said. However, Lumipulse’s use is limited to patients who present in a specialized care setting , whereas Roche’s Elecsys can be administered by primary care physicians. This earlier availability, the pharma said, can “significantly broaden” access to minimally invasive testing. In turn, primary care doctors can also “guide appropriate referrals,” allowing neurologists to “focus on the patients most likely to need advanced evaluation and treatment.” The Alzheimer’s space has been on a regulatory winning streak lately, including an approval for Biogen and Eisai’s subcutaneous Leqembi last month. The under-the-skin injection, branded Leqembi Iqlik, is indicated as a maintenance therapy for patients who have been on intravenous Leqembi for at least 18 months. The companies are looking to approval for Leqembi Iqlik as an induction option next year. In July, Lilly’s anti-amyloid therapy Kisunla secured a label expansion for a more gradual dosing schedule, which the pharma says could ease the risk of amyloid-related imaging abnormalities. Kisunla was first approved in July 2024 , about a year and a half behind Leqembi. Recent data established the long-term efficacy of Kisunla, which can keep amyloid plaques at bay for up to 2.5 years.

Drug Approval

100 Deals associated with Donanemab-AZBT

External Link

KEGG	Wiki	ATC	Drug Bank
D11500	Donanemab-AZBT	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Alzheimer Disease	United States	Eli Lilly & Co.	02 Jul 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psychotic Disorders	NDA/BLA	Canada	Eli Lilly Canada, Inc.	-
Neurocognitive Disorders	Phase 3	China	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Argentina	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Australia	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Poland	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	South Korea	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Spain	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Taiwan Province	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	United Kingdom	Eli Lilly & Co.	10 Oct 2022
Cognitive Dysfunction	Phase 2	United States	Eli Lilly & Co.	23 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04437511 (TRAILBLAZER-ALZ 2, PRNewswire) Manual	Phase 3	Alzheimer Disease	-	Kisunla	bzskmnhqzt(csbxpqcqfk): Difference = -0.6 View more	Positive	30 Jul 2025
				Neuroimaging Initiative (untreated external cohort)
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ and ALZ 2, Pubmed \| JAMA Neurol)	Not Applicable	Alzheimer Disease APOE ε4 allele number \| amyloid levels	3,030	Donanemab	rjnsmisdbt(zxoiegsfew) = mfkmugkntn gsrrwmdrlo (uvyxeddukz ) View more	Positive	01 May 2025
				Placebo	rjnsmisdbt(zxoiegsfew) = sbdqlxalsd gsrrwmdrlo (uvyxeddukz ) View more
NCT05108922 (TRAILBLAZER-ALZ 4, Pubmed \| Alzheimers Dement)	Phase 3	Alzheimer Disease amyloid plaque clearance	148	Donanemab	oltwvikjgq(etdseifycs) = ujenxgzfcf vqzczvgspy (cyihxnsntx ) View more	Positive	01 May 2025
				Aducanumab	oltwvikjgq(etdseifycs) = gaozvrxcyg vqzczvgspy (cyihxnsntx ) View more
NCT05738486 (TRAILBLAZER-ALZ 6, Company_Website 1 \| Company_Website 2) Manual	Phase 3	Alzheimer Disease	843	received two vials (700 mg) of donanemab for the first three infusions, then four vials (1400 mg) thereafterdonanemab for the first three infusions, then four vials (1400 mg) thereafter (Standard Dosing Regimen)	sgopmpgcia(vhkfycezuo) = gmoenpbovj mvecrwbtvl (iumwmgcirm ) View more	Positive	29 Oct 2024
				received 1 vial (350 mg) of donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion,donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion, and four vials (1400 mg) per infusion thereafter (Modified Titration)	sgopmpgcia(vhkfycezuo) = axvestqkue mvecrwbtvl (iumwmgcirm ) View more
NCT01837641 (CTgov)	Phase 1	Alzheimer Disease \| Cognitive Dysfunction \| Mild cognitive disorder	63	Placebo (Placebo IV)	vinarmitvp = bjeghcmydw mhcraptxtm (lbnliiyfkr, dneirnllbw - jivblcihbg) View more	-	04 Oct 2024
				LY3002813 (0.1 mg/kg / 0.3 mg/kg LY3002813 IV)	vinarmitvp = ldxhcjlpwa mhcraptxtm (lbnliiyfkr, fzwjhrqlma - qufjuobgke) View more
NCT05533411 (CTgov)	Phase 1	-	36	Placebo (Placebo)	gkajfyyvaa = gdwljbrpwi ywmlcvceti (hifqvyvkcv, mkhkfcuzqk - zirkrklkaf) View more	-	04 Oct 2024
				Donanemab (700 mg Donanemab)	gkajfyyvaa = hbnujitxac ywmlcvceti (hifqvyvkcv, etryhiocde - bdxeaceqxk) View more
NCT05567159 (CTgov)	Phase 1	-	42	Donanemab	vjidtbyjqs(kohjtcxbru) = jwhtdamvuq jwcqcieyvz (krytsjldaa, 23) View more	-	04 Oct 2024
NCT04437511 (FDA_CDER) Manual	Phase 3	Alzheimer Disease	1,736	KISUNLA	sepiflbajv(zcbytcxcrh): Difference = 2.92, P-Value = <0.0001 View more	Positive	02 Jul 2024
				Placebo
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ \| TRAILBLAZER-ALZ2, AAN2024)	Phase 2/3	number of microhemorrhages \| cortical superficial siderosis \| mean arterial pressure ... View more	2,031	Donanemab	kiianucmlj(xghhzuagvx) = mbnlfyozqx ecwnzdycmb (igertxjewu )	Positive	09 Apr 2024
NCT05108922 (TRAILBLAZER-ALZ 4, CTgov)	Phase 3	Alzheimer Disease \| Mild cognitive disorder	148	Aducanumab (Aducanumab)	ntyuwgvgqd = qldkbziboy ldlmuoipxa (nffnjktjzg, xbrmjzxszp - xajosovkcr) View more	-	02 Nov 2023
				Donanemab (Donanemab)	ntyuwgvgqd = afuduggdyl ldlmuoipxa (nffnjktjzg, etlajtuhid - fnjdveepea) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis